Go Pro
NASDAQ:NAGE

Niagen Bioscience Q2 2026 Earnings Report

Niagen Bioscience logo
$2.99 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$3.02 +0.03 (+1.00%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Niagen Bioscience EPS Results

Actual EPS
$0.01
Consensus EPS
$0.01
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Niagen Bioscience Revenue Results

Actual Revenue
$29.78 million
Expected Revenue
$29.95 million
Beat/Miss
Missed by -$170.00 thousand
YoY Revenue Growth
N/A

Niagen Bioscience Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Niagen Bioscience Earnings Headlines

Niagen Bioscience, Inc. (NAGE)
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company’s research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes.

The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand. Tru Niagen products are available in dietary supplement formulations intended to support NAD+ levels and cellular health. Niagen Bioscience also maintains intellectual property and conducts research related to NR and NAD+ biology.

The company was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name as part of its focus on the NIAGEN platform. Its products are marketed through direct-to-consumer and commercial channels in the United States and internationally. The company is led by Chief Executive Officer Robert N. Fried.

View Niagen Bioscience Profile